[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
We are performing a phase I clinical trial of combination-therapy with gemcitabine and epitope peptide derived from human vascular endothelial growth factor receptor (VEGFR) for advanced pancreas cancer. The aim of this study was to evaluate the safety, immunological response and tumor response. Six patients have been enrolled at present. During the clinical course, no major adverse events were observed. Additionally, two out of 6 cases showed a minor shrinkage of the tumor. Immunological response has not been analyzed yet. These results indicated that a combination-therapy with gemcitabine and epitope peptides derived from VEGFR could be tolerable.
Kim
Dal Ho
DH
Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
Shiozawa
Shunichi
S
Usui
Takebumi
T
Yoshimatsu
Kazuhiko
K
Otani
Taisuke
T
Tsunoda
Takuya
T
Nakamura
Yusuke
Y
Ogawa
Kenji
K
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D003131:Combined Modality Therapy / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000473:pathology / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000009:adverse effects / Q000276:immunology*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000276:immunology*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D000939:Epitopes; D010455:Peptides; D003841:Deoxycytidine; D040262:Receptors, Vascular Endothelial Growth Factor; D000093542:Gemcitabine